Description and Mechanism
Epclusa is a combination medication of Velpatasvir 100Mg and Sofosbuvir 400Mg used in the treatment of Hepatitis C Genotype 1, 2, 3, 4, 5, or 6 without or with cirrhosis (compensated) and HIV/Aids. For the treatment of chronic HCV with cirrhosis (decompensated) it is taken with ribavirin. Studies have revealed that the medication has higher cure rate of more than 90%.
It contains Velpatasvir, which is a NS5A inhibitor and Sofosbuvir, which is a NS5B (RNA) polymerase inhibitor. These works by inhibiting the replication of virus in the body. If taken for 12 weeks to 24 weeks then complete cure of the infection is possible.
- Used in cure of all Genotypes of HCV
- Simple regimen
- 94-99% cure rate
Each film coated tablet containsVelpatasvir 100Mg and Sofosbuvir 400Mg.
Dosage and Administration
- Epclusa should be taken strictly as prescribed by the doctor and for the given conditions
- It should be taken once daily with or without food with a whole glass of water
- Treatment may vary between 8weeks to 24 weeks as per the condition of the patient
- It may be prescribed with ribavirin.
Common side effects: fatigue, headache, and nausea.
Severe side effects: Liver failure, reappearance of Hepatitis B if it persisted before, etc. Call your doctor if any of these symptoms occur.
- It should not be taken withamiodarone as it may result in slower heartbeats
- It must not be taken while taking other suppositoriescomprising Sofosbuvir or Velpatasvir
- Tell your doctor if you are taking any over the counter medication or herbal product
- Tell your doctor if you are breastfeeding or pregnant as it may cause serious birth defects
|Active Ingredient(s)||Velpatasvir 100Mg +Sofosbuvir 400Mg|
|Strength||100mg +400 mg|
|Package Size||28 Tabs|
|Package Type||Plastic Bottle|
|Expiry||1 Year to 2 Years|
|Indication(s)||Hepatitic C Virus (HCV) Infection|